HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, reported a narrower net loss for the third quarter ended Sept. 30, 2026, and outlined progress in its heart attack assessment program. The company recorded a net loss of $3 million, or $0.05 per share, compared with a net loss of $5.3 million, or $0.15 per share, in the prior-year period. Operating expenses declined to $3.5 million from $5.3 million, while cash and cash equivalents totaled $6.1 million as of Sept. 30, 2026. HeartBeam also raised approximately $4 million in net proceeds during the fourth quarter through the date of the announcement, bringing pro forma cash to approximately $10.1 million. The company now expects full-year 2026 net operating cash outflow of $12 million to $12.5 million.
Operationally, HeartBeam advanced its strategic focus on heart attack assessment, receiving U.S. Food and Drug Administration Breakthrough Device Designation and acceptance into the agency's Total Product Life Cycle Advisory Program. The company completed enrollment of 486 patients in its HEADSTART-ACS study and reported positive results from its 132-patient ALIGN-ACS pilot study, which demonstrated higher specificity than standard 12-lead electrocardiograms with comparable sensitivity. HeartBeam plans to finalize the design of its U.S. pivotal study in the fourth quarter of 2026 and begin patient enrollment in the first quarter of 2027.
The financial improvement and clinical milestones matter for investors and the broader cardiac care market. HeartBeam is developing the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence, potentially allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. For details on the intended use of its technology, refer to the company's Cleared Indications for Use.
For a deeper look at HeartBeam's financial and operational results, the full press release is available at https://ibn.fm/8CLXO. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. Additional information on HeartBeam is available through its client profile.
The announcement was distributed through InvestorWire, a communications platform within the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication and related services, including editorial syndication to 5,000+ outlets and social media distribution.
